MedPath

Shock Wave Lithotripsy Versus Visual Cystolitholapaxy in The Management of Patients Presenting With Calcular Acute Urinary Retention: A Randomized Controlled Trial.

Phase 4
Conditions
Urinary Calculi
Registration Number
NCT02594631
Lead Sponsor
Mansoura University
Brief Summary

The aim of the study is to compare the safety and efficacy of ESWL and visual cystolitholapaxy in management of calcular acute urine retention.

Detailed Description

Patients who present with acute urinary retention due to stone in the urethra or urinary bladder will be randomly assigned to receive treatment either by extracorporeal shock wave lithotripsy or by endoscopic visual cystolitholapaxy where patients and stone characteristics will be recorded and the outcome including the intraoperative and postoperative complications and the stone free rate will be also evaluated

Recruitment & Eligibility

Status
UNKNOWN
Sex
Male
Target Recruitment
100
Inclusion Criteria
  1. Adult male patients presenting with acute urinary retention due to urethral or urinary bladder stones.
  2. with a stone size not more than 2 centimeters in greatest diameter.
  3. No more than 2 stones.
Exclusion Criteria
  1. Bladder cancer.
  2. Bladder replacement of any type.
  3. Infravesical obstruction, due to marked benign prostatic hyperplasia, prostate cancer, stricture urethra or external urethral meatal stenosis.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Stone free rate1 week

evaluation of stone free rate after the assigned intevention

Secondary Outcome Measures
NameTimeMethod
Adverse events after the assigned intervention1 month

evaluation of adverse events after the assigned intervention

Trial Locations

Locations (1)

Urology an Nephrology Center

🇪🇬

Mansoura, DK, Egypt

Urology an Nephrology Center
🇪🇬Mansoura, DK, Egypt
Mohamed I Ali, Dr
Contact
0020502262222
dr.m.ali.board@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.